Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner.

Aberdeen University could open biologics facility in India

Attendees at the Scottish Biologics Facility 10th anniversary included centre director Professor Andrew Porter, Lewis Macdonald MSP, facility manager Soumya Palliyil and head Aberdeen University School of Medicine, Medical Sciences and Nutrition, Professor Bhattacharya.
Attendees at the Scottish Biologics Facility 10th anniversary included centre director Professor Andrew Porter, Lewis Macdonald MSP, facility manager Soumya Palliyil and head Aberdeen University School of Medicine, Medical Sciences and Nutrition, Professor Bhattacharya.

Aberdeen University is celebrating a milestone 10-year anniversary with plans to launch a new drug facility in India.

Aberdeen’s Scottish Biologics Facility (SBF) has helped create diagnostic and therapeutic methods for diseases such as Alzheimer’s, cancer and arthritis.

The group started with a grant of around £90,000 but has since grown and has become key in developing new therapies and bringing them to market.

Aberdeen University is now considering plans to open an equivalent facility in India, staffed by former members of the SBF in the near future.

Professor Andrew Porter, professor of medical biotechnology at the university and director of the SBF, said: “We were born originally out of the Scottish Funding Council’s pooling exercise to encourage Scottish Universities to work together.

“Over the years we have developed the SBF into a facility with one foot firmly in academia, with collaborations across Scotland and throughout the UK and a continued commitment to scientific excellence, and the other foot in the business realm, capable of being a “drug-engine” and the start point of a treatment’s long journey to clinical approval.

“After starting off with a modest funding budget we have, over the last 10 years, secured millions of pounds of grants and spun out highly successful biotech companies.”

Already a subscriber? Sign in

[[title]]

[[text]]